目的 探讨儿童碳青霉烯类耐药肠杆菌目细菌（carbapenem-resistant Enterobacterales，CRE）感染的临床特征与分离株的分子特征。 方法 回顾性分析广东省人民医院2018年1月至2021年6月住院患儿的相关临床资料及感染情况，共获得非重复肠杆菌目细菌菌株1 098株。对所分离的66株CRE菌株进行药敏试验、PCR扩增和耐药相关基因测序，以研究分子流行情况。 结果 1 098株肠杆菌目细菌中，CRE检出率为6.01%（66/1 098）。66株CRE来自66例患儿，其中男37例（56%），女29例（44%）；年龄2 d至14岁，其中<1月龄16例（24%），1月龄~ 28例（42%），12月龄~ 11例（17%），>36月龄11例（17%）。被检出CRE的患儿主要分布于新生儿科（38例，58%）、儿科重症监护室（17例，26%）等科室；呼吸道标本（48%）、中段尿标本（21%）、血液标本（17%）位于标本检出前3位。CRE菌株以肺炎克雷伯菌（45株，68%）、大肠埃希菌（12株，18%）、阴沟肠杆菌（6株，9%）为主，对亚胺培南和厄他培南等碳青霉烯类及青霉素头孢类高度耐药，对常见抗菌药物耐药性均普遍偏高，仅对阿米卡星（14%）、左旋氧氟沙星（23%）、妥布霉素（33%）等耐药率相对较低。肺炎克雷伯菌碳青霉烯酶基因型以blaNDM（20株，44%）、blaIMP（10株，22%）及blaKPC（5株，11%）为主；大肠埃希菌碳青霉烯酶基因型以blaNDM为主（10株，83%）；经测序，blaNDM-1 24株，blaNDM-5 6株，blaIMP-4 5株，blaKPC-2 3株，部分基因型尚未明确。 结论 儿童CRE感染发生率高，且集中于1~12月龄婴儿；CRE对抗菌药物的耐药性普遍偏高，儿童感染CRE菌株的碳青霉烯酶以金属酶为主。
Abstract
Objective To study the clinical features of children with carbapenem-resistant Enterobacterales (CRE) infection and the molecular characteristics of isolated strains. Methods A retrospective analysis was performed on the clinical data and infection status of the children who were hospitalized in Guangdong Provincial People's Hospital from January 2018 to June 2021. A total of 1 098 non-repetitive strains of Enterobacterales were obtained. Drug sensitivity test, PCR amplification, and resistance-related gene sequencing were performed for 66 isolated CRE strains to observe molecular epidemiology. Results Among the 1 098 strains of Enterobacterales, the detection rate of CRE was 6.01% (66/1 098). The 66 CRE strains were isolated from 66 children, among whom there were 37 boys (56%) and 29 girls (44%), with an age of 2 days to 14 years. Among these 66 children, 16 (24%) had an age of <1 month, 28 (42%) had an age of 1-12 months, 11 (17%) had an age of 12-36 months, and 11 (17%) had an age of >36 months. The children with CRE were mainly distributed in the department of neonatology (38 children, 58%) and the pediatric intensive care unit (17 children, 26%). The top three types of specimens with CRE detection were respiratory specimens (48%), midstream urine specimens (21%), and blood specimens (17%). The CRE strains were mainly Klebsiella pneumoniae (45 strains, 68%), Escherichia coli (12 strains, 18%), and Enterobacter cloacae (6 strains, 9%), with high resistance to carbapenems (such as imipenem and ertapenem), penicillin, and cephalosporins, slightly high resistance to commonly used antibiotics, and relatively low resistance to amikacin (14%), levofloxacin (23%), and tobramycin (33%). The carbapenemase genotypes of Klebsiella pneumoniae strains were mainly blaNDM (20 strains, 44%), blaIMP (10 strains, 22%), and blaKPC (5 strains, 11%), and the carbapenemase genotypes of Escherichia coli strains were mainly blaNDM (10 strains, 83%). After sequencing, there were 24 blaNDM-1 strains, 6 blaNDM-5 strains, 5 blaIMP-4 strains, and 3 blaKPC-2 strains, and some genotypes were not identified. Conclusions There is a high incidence rate of CRE infection among children, mainly those aged 1-12 months. CRE generally has high resistance to antibacterial drugs, and metalloenzymes are the main type of carbapenemases for CRE strains in children.
关键词
碳青霉烯耐药肠杆菌目细菌 /
耐药性 /
分子流行病学 /
儿童
Key words
Carbapenem-resistant Enterobacterales /
Drug resistance /
Molecular epidemiology /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1 Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae[J]. Emerg Infect Dis, 2011, 17(10): 1791-1798. PMID: 22000347. PMCID: PMC3310682. DOI: 10.3201/eid1710.110655.
2 Brennan-Krohn T, Manetsch R, O'Doherty GA, et al. New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae[J]. Transl Res, 2020, 220: 14-32. PMID: 32201344. PMCID: PMC7293954. DOI: 10.1016/j.trsl.2020.02.008.
3 Chiotos K, Hayes M, Gerber JS, et al. Treatment of carbapenem-resistant Enterobacteriaceae infections in children[J]. J Pediatric Infect Dis Soc, 2020, 9(1): 56-66. PMID: 31872226. PMCID: PMC7047006. DOI: 10.1093/jpids/piz085.
4 付盼, 王传清, 俞蕙, 等. 中国儿童细菌耐药监测组2018年儿童细菌感染及耐药监测[J]. 中国循证儿科杂志, 2019, 14(5): 321-326. DOI: 10.3969/j.issn.1673-5501.2019.05.001.
5 尚红, 王毓三, 申子瑜, 等. 全国临床检验操作规程[M]. 4版. 北京: 人民卫生出版社, 2015.
6 Clinical and Laboratory Standards Institute. M100: performance standards for antimicrobial susceptibility testing, 32nd edition[EB/OL]. [2022-06-07]. https://www.clsi.org/standards/products/microbiology/documents/m100/.
7 Cornaglia G, Giamarellou H, Rossolini GM. Metallo-β-lactamases: a last frontier for β-lactams?[J]. Lancet Infect Dis, 2011, 11(5): 381-393. PMID: 21530894. DOI: 10.1016/S1473-3099(11)70056-1.
8 Dallenne C, Da Costa A, Decré D, et al. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae[J]. J Antimicrob Chemother, 2010, 65(3): 490-495. PMID: 20071363. DOI: 10.1093/jac/dkp498.
9 胡付品. CHINET中国细菌耐药监测结果: (2021年1-12月)[EB/OL]. [2022-06-07]. https://www.chinets.com/Document.
10 杨欣, 鲁利群, 黄莉, 等. 儿科碳青霉烯类耐药肺炎克雷伯菌感染危险因素及其耐药性[J]. 中华医院感染学杂志, 2020, 30(22): 3470-3473. DOI: 10.11816/cn.ni.2020-206730.
11 全国细菌耐药监测网. 2020年全国细菌耐药监测报告[J]. 中华检验医学杂志, 2022, 45(2): 122-136. DOI: 10.3760/cma.j.cn114452-20211118-00721.
12 Mrowiec P, Klesiewicz K, Ma?ek M, et al. Antimicrobial susceptibility and prevalence of extended-spectrum beta-lactamases in clinical strains of Klebsiella pneumoniae isolated from pediatric and adult patients of two Polish hospitals[J]. New Microbiol, 2019, 42(4): 197-204. PMID: 31609454.
13 何磊燕, 付盼, 吴霞, 等. 中国儿童细菌耐药监测组2020年儿童细菌耐药监测[J]. 中国循证儿科杂志, 2021, 16(6): 414-420. DOI: 10.3969/j.issn.1673-5501.2021.06.002.
14 付盼, 何磊燕, 王传清, 等. 中国儿童细菌耐药监测组2019年儿童细菌耐药监测[J]. 中国循证儿科杂志, 2021, 16(1): 43-49. DOI: 10.3969/j.issn.1673-5501.2021.01.002.
15 胡付品, 郭燕, 朱德妹, 等. 2020年CHINET中国细菌耐药监测[J]. 中国感染与化疗杂志, 2021, 21(4): 377-387. DOI: 10.16718/j.1009-7708.2021.04.001.
16 胡付品, 郭燕, 朱德妹, 等. 2019年CHINET三级医院细菌耐药监测[J]. 中国感染与化疗杂志, 2020, 20(3): 233-243. DOI: 10.16718/j.1009-7708.2020.03.001.
17 Yin L, He L, Miao J, et al. Carbapenem-resistant Enterobacterales colonization and subsequent infection in a neonatal intensive care unit in Shanghai, China[J]. Infect Prev Pract, 2021, 3(3): 100147. PMID: 34647006. PMCID: PMC8498732. DOI: 10.1016/j.infpip.2021.100147.
18 Flannery DD, Chiotos K, Gerber JS, et al. Neonatal multidrug-resistant gram-negative infection: epidemiology, mechanisms of resistance, and management[J]. Pediatr Res, 2022, 91(2): 380-391. PMID: 34599280. PMCID: PMC8819496. DOI: 10.1038/s41390-021-01745-7.
19 Rozaidi SW, Sukro J, Dan A. The incidence of nosocomial infection in the Intensive Care Unit, Hospital Universiti Kebangsaan Malaysia: ICU-acquired nosocomial infection surveillance program 1998-1999[J]. Med J Malaysia, 2001, 56(2): 207-222. PMID: 11771082.
20 Little ML, Qin X, Zerr DM, et al. Molecular diversity in mechanisms of carbapenem resistance in paediatric Enterobacteriaceae[J]. Int J Antimicrob Agents, 2012, 39(1): 52-57. PMID: 22055532. PMCID: PMC3237943. DOI: 10.1016/j.ijantimicag.2011.09.014.
21 Wu W, Feng Y, Tang G, et al. NDM metallo-β-lactamases and their bacterial producers in health care settings[J]. Clin Microbiol Rev, 2019, 32(2): e00115-18. PMID: 30700432. PMCID: PMC6431124. DOI: 10.1128/CMR.00115-18.
22 Khan AU, Maryam L, Zarrilli R. Structure, genetics and worldwide spread of New Delhi metallo-β-lactamase (NDM): a threat to public health[J]. BMC Microbiol, 2017, 17(1): 101. PMID: 28449650. PMCID: PMC5408368. DOI: 10.1186/s12866-017-1012-8.
23 Dong F, Zhang Y, Yao K, et al. Epidemiology of carbapenem-resistant Klebsiella pneumoniae bloodstream infections in a Chinese children's hospital: predominance of New Delhi metallo-β-lactamase-1[J]. Microb Drug Resist, 2018, 24(2): 154-160. PMID: 28594635. DOI: 10.1089/mdr.2017.0031.
24 Zhang X, Chen D, Xu G, et al. Molecular epidemiology and drug resistant mechanism in carbapenem-resistant Klebsiella pneumoniae isolated from pediatric patients in Shanghai, China[J]. PLoS One, 2018, 13(3): e0194000. PMID: 29558475. PMCID: PMC5860732. DOI: 10.1371/journal.pone.0194000.
25 廖兰凯, 廖雪莲, 康焰. 耐碳青霉烯类肠杆菌防控现状及研究进展[J]. 中华医院感染学杂志, 2019, 29(11): 1750-1755. DOI: 10.11816/cn.ni.2019-186124.
26 Fritzenwanker M, Imirzalioglu C, Herold S, et al. Treatment options for carbapenem-resistant gram-negative infections[J]. Dtsch Arztebl Int, 2018, 115(20-21): 345-352. PMID: 29914612. PMCID: PMC6172649. DOI: 10.3238/arztebl.2018.0345.
27 Alatoom A, Elsayed H, Lawlor K, et al. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa[J]. Int J Infect Dis, 2017, 62: 39-43. PMID: 28610832. DOI: 10.1016/j.ijid.2017.06.007.
28 余佳佳, 刘婧娴, 李媛睿, 等. 利用MALDI-TOF MS特异质量峰对耐碳青霉烯类肺炎克雷伯菌同源性的快速分型[J]. 中国感染控制杂志, 2019, 18(3): 206-212. DOI: 10.12138/j.issn.1671-9638.20193912.
基金
国家自然科学基金（81871734；82072380）；广东省基础与应用基础研究基金（2021A1515220022）。
PDF(645 KB)
